HUP9902405A2 - Szerotonin agonistát tartalmazó gyógyászati készítmények nátha és szénanátha kezelésére - Google Patents

Szerotonin agonistát tartalmazó gyógyászati készítmények nátha és szénanátha kezelésére

Info

Publication number
HUP9902405A2
HUP9902405A2 HU9902405A HUP9902405A HUP9902405A2 HU P9902405 A2 HUP9902405 A2 HU P9902405A2 HU 9902405 A HU9902405 A HU 9902405A HU P9902405 A HUP9902405 A HU P9902405A HU P9902405 A2 HUP9902405 A2 HU P9902405A2
Authority
HU
Hungary
Prior art keywords
substituents
alkyl
meaning
carbon atoms
phenyl
Prior art date
Application number
HU9902405A
Other languages
English (en)
Inventor
Kirk W. Johnson
Lee A. Phebus
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP9902405A2 publication Critical patent/HUP9902405A2/hu
Publication of HUP9902405A3 publication Critical patent/HUP9902405A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgyát nátha vagy allergiás nátha szimptómáinakkezelésére vagy enyhítésére szőlgáló gyógyászati készítmények ésezekkel történő kezelési eljárás képezi, amely készítményekbenhatóanyagként hatásős mennyiségben szerőtőnin 5-HT1F agőnista vanjelen; ezen készítmények emlősök kezelésére adhatók. E készítményekbenszelektív 5-HT1F receptőr agőnistaként valamely (I), (III), (IV), (V)vagy (VI) általánős képletű vegyületek vannak jelen. Az (I) általánősképletben a szűbsztitűensek jelentése a következő: A-B jelentése -CH-CH2- vagy -C=CH-; X jelentése hidrőgénatőm, halőgénatőm, 1-4szénatőmős alkőxi-, 1-4 szénatőmős alkiltiő-, 1-4 szénatőmős alkil-,benzil-őxi-, hidrőxi- vagy karbőxamidőcsőpőrt; n értéke 1-4; Arjelentése piridinil-, pirrőlil- vagy adőtt esetben szűbsztitűáltpirazőlilcsőpőrt. A (III) általánős képletben a szűbsztitűensekjelentése: A-B és X jelentése és n értéke a fentiekben megadőtt; Yjelentése őxigénatőm, kénatőm vagy egy vegyértékkötés; Ar jelentése 1-naftil-, 2-naftil-, fenil- vagy mőnőszűbsztitűált fenilcsőpőrt, ahőlszűbsztitűensként jelen lehet halőgénatőm, 1-4 szénatőmős alkxői-, 1-4szénatőmős alkiltiő-, 1-4 szénatőmős alkil-, benzil-őxi-, hidrőxil-vagy triflűőr-metil-csőpőrt. A (VI) általánős képletben aszűbsztitűensek jelentése: A-B, X, Y, Ar jelentése és n értékemegegyezik a (III) általánős képletnél megadőttakkal R1 jelentése 1-4szénatőmős alkilcsőpőrt; R2 jelentése 1-4 szénatőmős alkil-,ciklőalkil-(1-3 szénatőmős alkilén)-, aril-(1-3 szénatőmős alkilén)-vagy heterőaril-(1-3 szénatőmős alkilén)-csőpőrt; R3 jelentése 1-4szénatőmős alkil- vagy fenilcsőpőrt; R4 jelentése 1-4 szénatőmősalkil-, 3-7 szénatőmős ciklőalkil-, fenil-, szűbsztitűált fenil-,bifenilil-, naftil- vagy heterőciklűsős csőpőrt. A (IV) és (V)általánős képletekben a szűbsztitűensek jelentése a fentiszűbsztitűensekhez hasőnló. ŕ
HU9902405A 1996-08-16 1997-08-12 Pharmaceutical compositions containing a serotonin antagonist for the treatment of the common cold or allergic rhinitis HUP9902405A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2409696P 1996-08-16 1996-08-16

Publications (2)

Publication Number Publication Date
HUP9902405A2 true HUP9902405A2 (hu) 2000-04-28
HUP9902405A3 HUP9902405A3 (en) 2002-11-28

Family

ID=21818851

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902405A HUP9902405A3 (en) 1996-08-16 1997-08-12 Pharmaceutical compositions containing a serotonin antagonist for the treatment of the common cold or allergic rhinitis

Country Status (17)

Country Link
US (1) US5962473A (hu)
EP (1) EP0824917A3 (hu)
JP (1) JP2000516233A (hu)
KR (1) KR20000035789A (hu)
CN (1) CN1233180A (hu)
AU (1) AU716904B2 (hu)
BR (1) BR9711147A (hu)
CA (1) CA2263550A1 (hu)
CZ (1) CZ289998B6 (hu)
EA (1) EA001740B1 (hu)
HU (1) HUP9902405A3 (hu)
IL (1) IL128379A0 (hu)
NO (1) NO990701L (hu)
NZ (1) NZ334029A (hu)
PL (1) PL331708A1 (hu)
WO (1) WO1998006402A1 (hu)
YU (1) YU7699A (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1184373A4 (en) 1999-04-20 2004-10-20 Meiji Seika Kaisha TRICYCLIC CONNECTIONS
US6476051B2 (en) 1999-12-17 2002-11-05 Bristol-Myers Squibb Company Antipsychotic heterocycle compounds
WO2002051805A1 (de) 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indol-derivate
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2296956T5 (es) 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
KR20060127000A (ko) * 2003-11-17 2006-12-11 베링거 인겔하임 인터내셔날 게엠베하 신규한 피페리딘-치환된 인돌 유도체 또는 이의헤테로유도체 및 케모킨 수용체(ｃｃｒ-3)의 조절자로서의이의 용도
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
ATE531706T1 (de) * 2005-04-30 2011-11-15 Boehringer Ingelheim Int Neue piperidin-substituierte indole und ihre verwendung als ccr-3-modulatoren
WO2008049874A1 (en) 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh Piperidyl-propane-thiol ccr3 modulators
WO2012112567A1 (en) * 2011-02-15 2012-08-23 Georgetown University Small molecule inhibitors of agbl2
WO2015015378A2 (en) * 2013-08-02 2015-02-05 Pfizer Inc. Rorc2 inhibitors and methods of use thereof
WO2016120849A1 (en) 2015-01-30 2016-08-04 Pfizer Inc. Methoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
JP2018510131A (ja) 2015-01-30 2018-04-12 ファイザー・インク Ｒｏｒｃ２のスルホンアミド置換インドールモジュレーターおよびその使用方法
CN106045967B (zh) * 2015-04-08 2020-04-21 广东东阳光药业有限公司 取代杂环化合物及其在药物上的应用
CN106045966B (zh) * 2015-04-08 2020-04-21 广东东阳光药业有限公司 取代杂环化合物及其在药物上的应用
BR112019021992A2 (pt) 2017-04-21 2020-06-09 Kyn Therapeutics inibidores de ahr de indol e usos dos mesmos
CN115784911A (zh) * 2022-10-19 2023-03-14 山东省药学科学院 一种1-[2-(4-氯苯基)-乙基氨基]-2-丙醇的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443451A (en) * 1981-07-15 1984-04-17 Janssen Pharmaceutica N.V. Bicyclic pyrimidin-5-one derivatives
GB9125699D0 (en) * 1991-12-03 1992-01-29 Glaxo Group Ltd Device
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
TR199700993T1 (xx) * 1995-03-20 1998-03-21 Eli Lilly And Company 5-ikameli-3-(1,2,3,6-tetrahidropridin-4-il)- ve 3-(piperidin-4-il)-1H-indoller: yeni 5-HT1F agonistler.
AU5966196A (en) * 1995-06-08 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
US5942536A (en) * 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists

Also Published As

Publication number Publication date
BR9711147A (pt) 1999-08-17
HUP9902405A3 (en) 2002-11-28
EP0824917A3 (en) 2000-08-30
AU4061597A (en) 1998-03-06
JP2000516233A (ja) 2000-12-05
EA001740B1 (ru) 2001-08-27
CZ44099A3 (cs) 1999-10-13
CN1233180A (zh) 1999-10-27
WO1998006402A1 (en) 1998-02-19
CA2263550A1 (en) 1998-02-19
US5962473A (en) 1999-10-05
PL331708A1 (en) 1999-08-02
EP0824917A2 (en) 1998-02-25
YU7699A (sh) 2001-09-28
KR20000035789A (ko) 2000-06-26
EA199900206A1 (ru) 1999-08-26
NZ334029A (en) 2000-07-28
CZ289998B6 (cs) 2002-05-15
IL128379A0 (en) 2000-01-31
NO990701L (no) 1999-04-16
AU716904B2 (en) 2000-03-09
NO990701D0 (no) 1999-02-15

Similar Documents

Publication Publication Date Title
HUP9902405A2 (hu) Szerotonin agonistát tartalmazó gyógyászati készítmények nátha és szénanátha kezelésére
HUP9800417A2 (hu) 5-Szubsztituált-3-(1,2,3,6-tetrahidro-piridin-4-il)-1H-indolok és 5-szubsztituált-3-(piridin-4-il)-1H-indolok, alkalmazásuk mint új 5-HT agonisták, a vegyületeket tartalmazó gyógyszerkészítmények
UA27467C2 (uk) ПОХІДНІ ІНДОЛУ ЯК 5-НТ&lt;sub&gt;1&lt;/sub&gt; АГОНІСТИ ТА ПРОМІЖНІ СПОЛУКИ
FI934983A0 (fi) Kinuklidinderivat foer behandling av inflammatoriska och gastrointestinala sjukdomar
FR2714378B1 (fr) Dérivés de l&#39;indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
NO153220C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolinderivater.
HUP0001170A2 (hu) Hatóanyagként enzimidazol-2-karbamát-származékokat tartalmazó, vírusfertőzések és rák kezelésére alkalmas gyógyszerkészítmények
KR970704435A (ko) 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands)
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
CA2241904A1 (en) Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
BG103430A (en) FACTOR Xa INHIBITING HETEROCYCLIC DERIVATIVES
PL262105A1 (en) The method of manufacture of new derivatives of benzimidazole
TW430660B (en) Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
HUP0103063A2 (hu) Új 2H-piridazin-származékok, alkalmazásuk, ilyen hatóanyagot tartalmazó gyógyászati készítmények, és eljárás a hatóanyag előállítására
BG103947A (en) Derivatives of 9-oxymerythromycin
CY2466B1 (en) Phenyl dihydrobenzofuranes.
HUP9702042A2 (hu) 1,1,2-trifenil-but-1-én-származékok alkalmazása atherosclerosis kezelésére alkalmas gyógyszerkészítmények előállítására
HUP9700005A2 (hu) 2-Ureido-benzamid-származékok és ilyeneket hatóanyagként tartalmazó gyógyszerkészítmények
BR0015195A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas
HUT64061A (en) Process for producing indole derivatives and pharmaceutical compositions comprising same as active ingredient
ATE186301T1 (de) An den positionen 2 und 9 substituierte 4h-pyrido-(1,2-a)pyrimidin-4-one
CA2274686A1 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
EP1086099A4 (en) COMPOUNDS BASED ON SULFONIC ACID OR SULFONYLAMINO N- (HETEROARALKYL) -AZAHETEROCYCLYLAMIDE
CA2244777A1 (en) 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
NO158017C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.